Darrell has been appointed a Tier 2 Canada Research Chair in HIV Prevention and STI Research. More information can be found here.
Darrell has been appointed a Tier 2 Canada Research Chair in HIV Prevention and STI Research. More information can be found here.
As of June 25, 2020, the Options Lab received federal funding for a COVID-19 clinical trial which aims to investigate if a 14 day course of oral Kaletra (lopinavir/ritonavir), which is currently used as one strategy for HIV post-exposure prophylaxis (PEP), is effective as COVID-19 PEP. More information can be found here.
As of June 8, 2020, Darrell has been elected to the Governing Council of the International AIDS Society (IAS). You can read more about this here.
Recent Comments